IMMX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Immix Biopharma Inc (IMMX) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock shows strong upside potential based on analyst ratings, a promising drug pipeline, and a favorable technical setup. Despite the lack of recent news or congress trading data, the company's focus on advancing its novel therapy, NXC-201, and its positive Phase 1 and 2 trial results make it a compelling long-term investment opportunity.
The stock's technical indicators show bullish moving averages (SMA_5 > SMA_20 > SMA_200), indicating an upward trend. However, the MACD histogram is negative and expanding, which may suggest short-term weakness. RSI is neutral at 63.535, and the stock is trading near its resistance level of R1: 8.84. Overall, the technical setup leans bullish for long-term investors.
Analysts have given the stock an Outperform rating with a price target of $14, implying 108% upside potential.
Positive Phase 1 and Phase 2 trial results for NXC-201, a novel BCMA-directed CAR-T therapy.
Encouraging feedback from key opinion leaders, increasing the probability of approval for NXC-201.
Lack of recent news or significant trading trends from hedge funds or insiders.
Financials show no revenue and a negative net income, though the YoY improvement in net income is a slight positive.
In Q3 2025, the company reported no revenue growth (0% YoY), a net income of -$7,585,692 (up 6.10% YoY), and an EPS of -0.24 (unchanged YoY). While the company is not yet profitable, its focus on advancing its drug pipeline may lead to future revenue generation.
Analysts are bullish on IMMX. Mizuho initiated coverage with an Outperform rating and a $14 price target, citing the de-risked nature of NXC-201 following positive trial results. H.C. Wainwright raised its price target to $12 from $8, maintaining a Buy rating. Both ratings suggest strong upside potential for the stock.
